Literature DB >> 12429164

In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue.

Michael Seidler1, Stefan Uckert, Eginhard Waldkirch, Christian G Stief, Matthias Oelke, Dimitrios Tsikas, Michael Sohn, Udo Jonas.   

Abstract

OBJECTIVES: The discovery of nitric oxide (NO) as one of the major effectors in penile erectile function has led to the development of various drugs which are able to elevate intracellular levels of cGMP. Recently, a novel class of NO donors have been developed, exemplified by S-nitroso-glutathione (GSNO) and S-nitroso-N-acetylcysteine-ethylester (SNACET), as well as compounds combining both phosphodiesterase inhibitory and NO donating activity, such as NCX 911 (sildenafil nitrate). In our study, we assessed the effects of GSNO, SNACET and NCX 911 on adrenergic tension and electrically induced relaxation of isolated human corpus cavernosum (HCC) and the in vitro formation of cGMP. Effects were compared to those of sodium nitroprusside (SNP) and sildenafil citrate.
MATERIALS AND METHODS: Using the organ bath technique, drug effects were investigated on norepinephrine-induced tension and electrically induced relaxation of HCC. HCC strips were exposed to increasing concentrations of the compounds (0.01/0.1-10/100 microM) and the accumulation of cGMP was determined by means of a radioimmunoassay.
RESULTS: Relaxation of HCC induced by means of electrical field stimulation (EFS) was abolished by tetrotodoxin, guanylyl cyclase inhibitor ODQ and nitric oxide synthase inhibitor L-NNA. Adrenergic tension of HCC strips was dose-dependently reversed by the drugs. The rank order of potency was: SNP > GSNO > NCX911 > sildenafil > SNACET. Compounds also dose-dependently increased EFS-induced amplitudes of relaxation (SNP > NCX911 > sildenafil > SNACET/GSNO). Relaxing effects of the drugs were paralleled by an increase in tissue levels of cGMP.
CONCLUSION: Our results provide a rationale for future use of NCX 911 and S-nitrosothiols in the pharmacotherapy of erectile dysfunction (ED). Since the compounds are assumed to exert no considerable hemodynamic effects, they might be developed into new oral treatments for ED.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429164     DOI: 10.1016/s0302-2838(02)00397-4

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

Review 1.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

2.  Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action.

Authors:  A S Leitão Junior; R M Campos; J B G Cerqueira; M C Fonteles; C F Santos; G de Nucci; E H S Sousa; L G F Lopes; L F Gonzaga-Silva; N R F Nascimento
Journal:  Int J Impot Res       Date:  2015-10-29       Impact factor: 2.896

3.  Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells.

Authors:  Saima Muzaffar; Nilima Shukla; Amit Srivastava; Gianni D Angelini; Jamie Y Jeremy
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 4.  The future is today: emerging drugs for the treatment of erectile dysfunction.

Authors:  Maarten Albersen; Alan W Shindel; Kuwong B Mwamukonda; Tom F Lue
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

5.  Effects of arginase inhibitors on the contractile and relaxant responses of isolated human penile erectile tissue.

Authors:  Johan M Lorenzen; Stefan Ückert; Friedemann Scheller; Hermann Haller; Markus A Kuczyk
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

Review 6.  The role of nitric oxide in erectile dysfunction: implications for medical therapy.

Authors:  Arthur L Burnett
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

Review 7.  S-Nitroso-N-acetyl-L-cysteine ethyl ester (SNACET) and N-acetyl-L-cysteine ethyl ester (NACET)-Cysteine-based drug candidates with unique pharmacological profiles for oral use as NO, H2S and GSH suppliers and as antioxidants: Results and overview.

Authors:  Dimitrios Tsikas; Kathrin S Schwedhelm; Andrzej Surdacki; Daniela Giustarini; Ranieri Rossi; Lea Kukoc-Modun; George Kedia; Stefan Ückert
Journal:  J Pharm Anal       Date:  2017-12-13

8.  Synthesis and Modeling Studies of Furoxan Coupled Spiro-Isoquinolino Piperidine Derivatives as NO Releasing PDE 5 Inhibitors.

Authors:  Swami Prabhuling; Yasinalli Tamboli; Prafulla B Choudhari; Manish S Bhatia; Tapan Kumar Mohanta; Ahmed Al-Harrasi; Zubaidha K Pudukulathan
Journal:  Biomedicines       Date:  2020-05-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.